Hematopoietic stem cells: Source matters

Current Stem Cell Research and Therapy

Volumn 3, Issue 4, 2008, Pages 229-236

  Haspel, Richard L ^a   Miller, Kenneth B ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Bone marrow transplant; Cord blood transplant; Hematopoietic stem cell transplant; Peripheral blood stem cell transplant

Indexed keywords

BLOOD CELL; BONE MARROW CELL; CELL SEPARATION; CYTOLOGY; FETUS BLOOD; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOLOGY; PHYSIOLOGY; REVIEW;

BLOOD CELLS; BONE MARROW CELLS; CELL SEPARATION; FETAL BLOOD; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS;

EID: 65349164536     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488808786734033     Document Type: Review

References (53)

1. Appelbaum FR. Hematopoietic-cell transplantation at 50. N Engl J Med 2007; 357: 1472-5.
2. Center for International Blood and Marrow Transplant Research (CIBMTR). 2007. Allogeneic stem cell sources by recipient age 1997-2006. http://www.cibmtr.org/SERVICES/Observational_Research/Summary_Slides/index.html Accessed 1/24 /08.
3. Kogler G, Enczmann J, Rocha V, Gluckman E, Wernet P. High-resolution HLA typing by sequencing for HLA-A, -B, -C, -DR, - DQ in 122 unrelated cord blood/patient pair transplants hardly improves long-term clinical outcome. Bone Marrow Transplant 2005; 36: 1033-41.
4. Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110: 4576-83.
5. Government Accounting Office (GAO). 2002. Bone Marrow Transplants. http://www.gao.gov/new.items/d03182.pdf. Accessed 1/24/08.
6. National Marrow Donor Program (NMDP). (2008) Unrelated Donor Search Process, Step by Step 2008. http://www.marrow.org/-PHYSICIAN/URD_Search_and_Tx/Searching_for_an_URD_or_CBU/URD_Search_Process_Step_by_Ste/index.html. Accessed 3/19/08.
7. FACT, JACIE. FACT-JACIE International Standards for Cellular Therapy Product Collection, Processing and Administration. Third ed. 2006.
8. AABB. (2007) Donor History Questionnaire for Allogeneic HPC, Apheresis and HPC, Marrow (HPC-DHQ) http://www.aabb.org/-Content/Donate_Blood/Donor_History_Questionnaires/HPC_Donor_History_Questionnaire Accessed 3/19/08.
9. th ed. 2004.
10. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175-81.
11. Blaise D, Kuentz M, Fortanier C, et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol 2000; 18: 537-46.
12. Couban S, Simpson DR, Barnett MJ, et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002; 100:1525-31.
13. Schmitz N, Beksac M, Hasenclever D, et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood 2002; 100: 761-7.
14. Anderlini P, Champlin RE. Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges. Blood 2008; 111: 1767-72.
15. Comenzo RL, Malachowski ME, Miller KB, et al. Large-volume leukapheresis for collection of mononuclear cells for hematopoietic rescue in Hodgkin's disease. Transfusion 1995; 35: 42-5.
16. Tigue CC, McKoy JM, Evens AM, Trifilio SM, Tallman MS, Bennett CL. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant 2007; 40: 185-92.
17. Horowitz MM, Confer DL. Evaluation of hematopoietic stem cell donors. Hematology Am Soc Hematol Educ Program 2005; 469-75.
18. Bredeson C, Leger C, Couban S, et al. An evaluation of the donor experience in the canadian multicenter randomized trial of bone marrow versus peripheral blood allografting. Biol Blood Marrow Transplant 2004; 10: 405-14.
19. Favre G, Beksac M, Bacigalupo A, et al. Differences between graft product and donor side effects following bone marrow or stem cell donation. Bone Marrow Transplant 2003; 32: 873-80.
20. Heldal D, Brinch L, Tjonnfjord G, et al. Donation of stem cells from blood or bone marrow: results of a randomised study of safety and complaints. Bone Marrow Transplant 2002; 29: 479-486.
21. Rowley SD, Donaldson G, Lilleby K, Bensinger WI, Appelbaum FR. Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation. Blood 2001; 97: 2541-8.
22. Aleem A, Lovell R, Holder K, Chakarbarti S, James J, Milligan DW. Performing bone marrow harvest on an outpatient basis: a single center UK experience. Acta Haematol 2004; 112: 200-2.
23. AABB, FACT, ABC, ICCBBA, NMDP, AATB, ASBMT, ARC, ASFA, ISCT. Circular of Information for the use of Cellular Therapy Products. 2005; 1-18.
24. Sauer-Heilborn A, Kadidlo D, McCullough J. Patient care during infusion of hematopoietic progenitor cells. Transfusion 2004; 44: 907-16.
25. Dalle JH, Duval M, Moghrabi A, et al. Results of an unrelated transplant search strategy using partially HLA-mismatched cord blood as an immediate alternative to HLA-matched bone marrow. Bone Marrow Transplant 2004; 33: 605-11.
26. Chow R, Nademanee A, Rosenthal J, et al. Analysis of hematopoietic cell transplants using plasma-depleted cord blood products that are not red blood cell reduced. Biol Blood Marrow Transplant 2007; 13: 1346-57.
27. Food and Drug Administration (FDA). 2006. Draft Guidance for Industry: Minimally Manipulated, Unrelated, Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic Reconstitution in Patients with Hematological Malignancies. http://www.fda. gov/cber/gdlns/cordbld.pdf. Accessed 1/24/08.
28. Laroche V, McKenna DH, Moroff G, Schierman T, Kadidlo D, McCullough J. Cell loss and recovery in umbilical cord blood processing: a comparison of postthaw and postwash samples. Transfusion 2005; 45: 1909-16.
29. Hahn T, Bunworasate U, George MC, et al. Use of nonvolumereduced (unmanipulated after thawing) umbilical cord blood stem cells for allogeneic transplantation results in safe engraftment. Bone Marrow Transplant 2003; 32: 145-50.
30. Nagamura-Inoue T, Shioya M, Sugo M, et al. Wash-out of DMSO does not improve the speed of engraftment of cord blood transplantation: follow-up of 46 adult patients with units shipped from a single cord blood bank. Transfusion 2003; 43: 1285-95.
31. Schmitz N, Beksac M, Bacigalupo A, et al. Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial. Haematologica 2005; 90: 643-8.
32. Mohty M, Kuentz M, Michallet M, et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. Blood 2002; 100: 3128-34.
33. Flowers ME, Parker PM, Johnston LJ, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 2002; 100: 415-9.
34. Elfenbein GJ, Sackstein R. Primed marrow for autologous and allogeneic transplantation: a review comparing primed marrow to mobilized blood and steady-state marrow. Exp Hematol 2004; 32: 327-39.
35. Remberger M, Beelen DW, Fauser A, Basara N, Basu O, Ringden O. Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. Blood 2005; 105: 548-51.
36. Eapen M, Logan BR, Confer DL, et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant 2007; 13: 1461-8.
37. Rocha V, Cornish J, Sievers EL, et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001; 97: 2962-71.
38. Eapen M, Rubinstein P, Zhang MJ, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 2007; 369: 1947-54.
39. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004; 351: 2265-75.
40. Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004; 351: 2276-85.
41. Sanz MA. Cord-blood transplantation in patients with leukemia--a real alternative for adults. N Engl J Med 2004; 351: 2328-30.
42. Takahashi S, Iseki T, Ooi J, et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood 2004; 104: 3813-20.
43. Takahashi S, Ooi J, Tomonari A, et al. Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. Blood 2007; 109: 1322-30.
44. Gluckman E. Current status of umbilical cord blood hematopoietic stem cell transplantation. Exp Hematol 2000; 28: 1197-05.
45. Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002; 100: 1611-8.
46. Kamani N, Spellman S, Hurley CK, et al. State of the art review: HLA matching and outcome of unrelated donor umbilical cord blood transplants. Biol Blood Marrow Transplant 2008; 14: 1-6.
47. Stevens CE, Scaradavou A, Carrier C, Carpenter C, Rubinstein P. An Empirical Analysis of the Probability of Finding a Well Matched Cord Blood Unit: Implications for a National Cord Blood Inventory. Blood 2005; 106: 579a.
48. Ballen KK, Spitzer TR, Yeap BY, et al. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant 2007; 13: 82-9.
49. Barker JN, Weisdorf DJ, DeFor TE, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005; 105: 1343-7.
50. Brunstein CG, Barker JN, Weisdorf DJ, et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplant outcomes in 110 adults with hematological disease. Blood 2007; 110: 3064-70.
51. Hofmeister CC, Zhang J, Knight KL, Le P, Stiff PJ. Ex vivo expansion of umbilical cord blood stem cells for transplantation: growing knowledge from the hematopoietic niche. Bone Marrow Transplant 2007; 39: 11-23.
52. Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003; 425: 841-6.
53. Devine SM, Flomenberg N, Vesole DH, et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 1095-1102.